Paradromics

At Parafin, we're building the infrastructure that powers embedded financial services for marketplaces, vertical SaaS platforms, and payment processors. Our team of innovators hails from Stripe, Square, Plaid, Coinbase, Robinhood, and CERN-united by a mission to grow small businesses through better access to capital. We believe in solving complex financial challenges with elegant technology, abstracting away the intricacies of underwriting, compliance, and servicing so platforms can focus on what they do best. Our engineers own critical systems end-to-end, from frontend polish to backend infrastructure, with an emphasis on shipping reliable, scalable products that serve hundreds of thousands of businesses. We thrive on collaboration across functions and technical depth. Whether building AI-powered underwriting models trained on over a billion data points or crafting seamless white-labeled integrations, we prioritize thoughtful engineering over rigid processes. Our culture rewards curiosity, ownership, and the relentless pursuit of better ways to serve small businesses. As a Series C company backed by Ribbit Capital, Thrive Capital, GIC, and Notable Capital, we've scaled to $25B+ in offers extended while maintaining the startup mindset that got us here. We optimize for impact, not facetime-which means building systems and teams that can move fast without breaking things.

We're a team building tools that help developers focus on writing code instead of wrestling with infrastructure. Founded by the creators of Dapr and KEDA, we know firsthand how complex distributed systems can be - that's why we created Diagrid Catalyst and Diagrid Enterprise. Our goal is to make AI agents and workflows reliable, secure, and actually workable in production environments, not just in demos. What makes us different is our open-source DNA. Everyone at Diagrid contributes to open source, whether that's submitting code, maintaining documentation, presenting at conferences, or helping users in Discord. We don't believe in vendor lock-in - our products work with standard open-source Dapr, not some proprietary fork. We've been contributing to Dapr since day one, and we're proud to be one of the largest contributors to the CNCF project.

In 2000, five IIM graduates founded Fractal with a vision to power every human decision in the enterprise. What started as an analytics SaaS business in the BFSI and consumer goods segment has evolved into a publicly listed global enterprise AI company, now employing over 4,500 professionals across 17 global locations. The founders recognized early on that Fortune 500 companies needed more than just data - they needed intelligence that could transform how decisions were made across growth, supply chains, pricing, and customer experience. Today, Fractal partners with some of the world's most admired companies to embed AI into critical business decisions, investing more than 5% of annual revenue in research and development. The company's unique approach integrates expertise in AI, engineering, and design to deliver enterprise-level transformations that are both scalable and impactful. From pioneering agentic AI platforms like Cogentiq to launching intelligent sales agents and healthcare AI solutions, Fractal continues to push the boundaries of what's possible with artificial intelligence. The company's journey from a Mumbai-based startup to a dual-headquartered organization with presence across North America, EMEA, and Asia-Pacific exemplifies its commitment to being where its clients are, delivering value through sustained innovation and human-centric AI solutions.

Founded in 1978, Biogen stands as one of the world's first global biotechnology companies, pioneering innovative science to deliver transformative medicines for patients facing devastating neurological diseases. Headquartered in Cambridge, Massachusetts with major manufacturing operations in North Carolina's Research Triangle Park, Biogen has spent nearly 50 years pushing the boundaries of what's possible in biotechnology. The company focuses on some of the most challenging disease areas including multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus, and postpartum depression. Biogen's mission is rooted in deep scientific expertise and the courage to take bold risks. With close to 2,500 U.S. employees in research and development alone, plus over 1,500 manufacturing employees in North Carolina, Biogen leverages its understanding of human biology to advance first-in-class treatments and therapies. The company's culture - described as "Caring Deeply. Working Fearlessly. Changing Lives™" - reflects its unwavering commitment to patients, combining rigorous science with a profound sense of purpose to create value for shareholders and communities worldwide. Through continuous innovation in neurology, immunology, and rare diseases, Biogen aims to turn scientific breakthroughs into tangible hope for millions of patients.

Somos is a global provider of telephone number and identity information services, serving as the trusted authority for all telephone numbers used in North America. The company operates critical numbering registries as a FCC-appointed administrator, delivering comprehensive solutions for fraud mitigation, data integrity, routing optimization, and number administration across the telecommunications ecosystem. Somos enables businesses, service providers, and enterprises to protect customer communications against fraud, errors, and compliance risks through its portfolio of registry management and data solutions. Through products like TFNRegistry for toll-free number administration, RealNumber for fraud prevention, and SomosID for IoT asset intelligence, Somos establishes trust at every layer of digital communications. The company powers the North American Numbering Plan Administration (NANPA), manages text-enabled toll-free services through TSSRegistry, and provides authoritative routing data that ensures accurate message delivery. With a presence across multiple U.S. locations, Somos serves financial institutions, telecom providers, the education sector, and IoT enterprises with tools that strengthen identity verification and maintain the integrity of global communications infrastructure.

Clario is a leading healthcare research and technology company that generates high-quality clinical evidence for pharmaceutical, biotechnology, and medical device partners. Formerly known as ERT and Bioclinica, Clario brings over 50 years of expertise to clinical trial management. The company fuses deep scientific knowledge with global scale to deliver the broadest endpoint technology platform available. Clario has supported nearly 900 regulatory approvals across 19,000 studies spanning almost 600 indications, demonstrating a proven track record of accelerating drug development and reducing trial risk. Clario's comprehensive solutions span cardiac safety, electronic clinical outcome assessments (eCOA), medical imaging, precision motion, respiratory endpoints, and clinical adjudication. The company supports decentralized, hybrid, and site-based trials with advanced cloud-native technologies and AI-powered tools. With a presence in more than 80,000 sites worldwide, Clario's science-informed approach ensures the richest evidence possible for life-changing therapies. Their mission is to transform lives by unlocking better evidence, uniting clinical science, innovative technology, and global expertise to bring new treatments to patients faster.